drugset / Trial / NCT02852213

A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

NCT02852213 ↗

NaSingle-groupOpen-labelTreatment

Summary

The overall objective of this study is to determine the safety and efficacy of AAV2-hAADC delivered to the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) in children with aromatic L-amino acid decarboxylase (AADC) deficiency.

Timeline

Start
2016-07-01
Primary completion
2029-03
Completion
2037-03

Outcome

Met primary endpoint

paper Both the primary and secondary endpoints of the study were met. PMID 34253733 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Eladocagene Exuparvovec Gene therapy (AAV / viral vector) 1.3e+11 vg Other
Subject Eladocagene Exuparvovec Gene therapy (AAV / viral vector) 4.2e+11 vg Other
Subject Eladocagene Exuparvovec Gene therapy (AAV / viral vector) 1.3e+12 vg Other
Subject Eladocagene Exuparvovec Gene therapy (AAV / viral vector) 1.6e+12 vg Other